Literature DB >> 8347177

Reversal of 6-mercaptopurine and 6-methylmercaptopurine ribonucleoside cytotoxicity by amidoimidazole carboxamide ribonucleoside in Molt F4 human malignant T-lymphoblasts.

E H Stet1, R A De Abreu, J P Bökkerink, T M Vogels-Mentink, L H Lambooy, F J Trijbels, R C Trueworthy.   

Abstract

Cytotoxicity of 6-mercaptopurine (6MP) and 6-methylmercaptopurine ribonucleoside (Me-MPR) was studied in Molt F4 human malignant lymphoblasts. Both drugs are converted into methylthioIMP (Me-tIMP), which inhibits purine de novo synthesis. Addition of amidoimidazole carboxamide ribonucleoside (AICAR) circumvented inhibition of purine de novo synthesis, and thus partly prevented 6MP and Me-MPR cytotoxicity. Purine nucleotides, and especially adenine nucleotides, were recovered by addition of AICAR. Under these conditions, Me-tIMP formation decreased. The results of this study indicate that formation of Me-tIMP may be important for 6MP cytotoxicity in Molt F4 cells. These data suggest that depletion of adenine nucleotides is the main cause for Me-tIMP cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8347177     DOI: 10.1016/0006-2952(93)90534-4

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  6 in total

1.  Methotrexate and erythro-9-(2-hydroxynon-3-yl) adenine therapy for rat adjuvant arthritis and the effect of methotrexate on in vivo purine metabolism.

Authors:  Joseph E Baggott; Sarah L Morgan
Journal:  Eur J Pharm Sci       Date:  2007-03-01       Impact factor: 4.384

2.  AMP-activated protein kinase-independent inhibition of hepatic mitochondrial oxidative phosphorylation by AICA riboside.

Authors:  Bruno Guigas; Nellie Taleux; Marc Foretz; Dominique Detaille; Fabrizio Andreelli; Benoit Viollet; Louis Hue
Journal:  Biochem J       Date:  2007-06-15       Impact factor: 3.857

3.  6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity.

Authors:  C Cuffari; Y Théorêt; S Latour; G Seidman
Journal:  Gut       Date:  1996-09       Impact factor: 23.059

4.  Decrease in S-adenosylmethionine synthesis by 6-mercaptopurine and methylmercaptopurine ribonucleoside in Molt F4 human malignant lymphoblasts.

Authors:  E H Stet; R A De Abreu; J P Bökkerink; H J Blom; L H Lambooy; T M Vogels-Mentink; A C de Graaf-Hess; B van Raay-Selten; F J Trijbels
Journal:  Biochem J       Date:  1994-11-15       Impact factor: 3.857

5.  Increased sensitivity to thiopurines in methylthioadenosine phosphorylase-deleted cancers.

Authors:  Sally A Coulthard; Christopher P F Redfern; Svante Vikingsson; Malin Lindqvist-Appell; Karin Skoglund; Ingrid Jakobsen-Falk; Andrew G Hall; Gordon A Taylor; Linda A Hogarth
Journal:  Mol Cancer Ther       Date:  2011-01-31       Impact factor: 6.261

Review 6.  Mercaptopurine/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction.

Authors:  Kjeld Schmiegelow; Stine N Nielsen; Thomas L Frandsen; Jacob Nersting
Journal:  J Pediatr Hematol Oncol       Date:  2014-10       Impact factor: 1.289

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.